AI Medical Technology builds Dermalyser, a CE-marked software device that analyzes dermatoscopic images of skin lesions to support clinicians assessing suspected melanoma. Founded in 2020 in Stockholm, Sweden, by a team of physicians and technologists including CEO Christoffer Ekström and co-founder Panos Papachristou, the company develops diagnostic-support tools aimed at primary care settings where dermatology expertise is scarce.
Dermalyser runs on a smartphone fitted with a dermatoscope attachment: a clinician captures an image of a lesion, and the AI returns a decision-support read in seconds. In a clinical study across primary care facilities, the tool reported an AUROC of 0.960, with sensitivity of 95.2% and specificity of 84.5% overall, rising to 100% sensitivity for invasive melanomas. The company secured CE Mark certification in 2025 and is targeting FDA 510(k) clearance for the US market by 2027.
Dermalyser suits primary care practices, general practitioners, and clinics without on-site dermatologists who need a second opinion on suspicious lesions before referral. The company runs a 30-day free trial, with subscription plans starting around $200 a month for smaller practices; larger deployments require contacting AI Medical Technology directly for pricing.
